Drugs / Tetravalent influenza vaccine developed by Sinovac Biotech Co.
Tetravalent influenza vaccine developed by Sinovac Biotech Co.
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05494047 | Jul 2022 → May 2023 | influenza | Pontificia Universidad Catolica de Chile | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tetravalent influenza vaccine developed by Sinovac Biotech Co. | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05494047 ↗ |
| Modality | Vaccine | “quadrivalent inactivated influenza vaccines” NCT05494047 ↗ |